On September 17, 2026, Jianxin Yang purchased 132,500 shares of CSTONE PHARMA-B on the SEHK open market at an average of HKD 5.2361 per share, involving about HKD 693,783, representing an on-exchange active trade, i.e. a direct dealing in the secondary market.
Prior to the acquisition, Jianxin Yang's long position in CSTONE PHARMA-B was 84.28 million shares, representing 5.28%; following the acquisition, the holding changed to 84.42 million shares, with the long position ratio rising to 5.29%.
Source: Hong Kong Exchanges and Clearing Limited.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments